Wednesday, Sep 23 2020
CDI Labs HuProt™ Protein Arrays Instrumental in Recent Study of Multisystem Inflammatory Syndrome in Children (MIS-C)
Proteomics company CDI Laboratories products used in important study of MIS-C and its relationship to SARS-CoV-2 (COVID-19) infection.
MAYAGUEZ, Puerto Rico and BALTIMORE, Sept. 23, 2020 - CDI Laboratories, Inc. HuProt™ protein microarray provided important data on a recent high impact paper comparing the immune profiles of MIS-C, healthy children and individuals with COVID-19.
(see https://www.newswise.com/coronavirus/mount-sinai-researchers-study-sars-cov2-caussed-mis-c)
In recent months some children that have been infected with SARS-CoV-2 (COVID-19) have developed an inflammatory problem that was initially recognized as very similar in presentation to Kawasaki disease (KD), an acute systemic vasculitis.
A recent paper has mapped the cellular and serological immune dysfunction underlying this novel pediatric inflammatory syndrome associated with SARS-CoV-2, and helped define how this unique disease differs from Kawasaki disease..
Mapping Systemic Inflammation and Antibody Responses in Multisystem
Inflammatory Syndrome in Children (MIS-C)
Conor Gruber, et al.
PII: S0092-8674(20)31231-9
DOI: https://doi.org/10.1016/j.cell.2020.09.034
Reference: CELL 11634
In the above paper auto-antigen reactivity of MIS-C plasma was assayed with CDI Laboratories HuProt protein arrays which contain 81% of the human proteome. This work revealed both known autoimmune-associated autoantibodies (anti-La) and novel candidates that recognize endothelial, gastrointestinal and immune-cell antigens unique to organs affected by MIS-C.
"CDI is very proud that our HuProt array was so useful in looking into this perplexing side effect of COVID-19 infection in children," said Scott Paschke, CDI VP. "Furthermore, PhIP-Seq technology was also used to look at linear epitopes of auto-antibodies, which is another technology that CDI has recently added."
About CDI – CDI is a privately-owned biotechnology corporation, that focuses on contract research services to enable R&D of future therapeutic and diagnostic tools to proceed more rapidly and cost-effectively. The Company exports products and offers services worldwide and is rapidly expanding its client base and its academic and industrial collaborations.
For more information, visit https://cdi.bio/ or https://cdi.bio/antygen.
Media Contact:
Scott Paschke, VP
CDI Laboratories Inc
518-534-2881 (direct)